Publicacións en colaboración con investigadores/as de Harvard Medical School (17)

2024

  1. Adaptation and Validation of the Hooked on Nicotine Checklist (HONC) with Spanish Adolescents

    Archivos de Bronconeumologia, Vol. 60, Núm. 5, pp. 279-284

  2. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank

    Clinical and experimental rheumatology, Vol. 42, Núm. 2, pp. 277-287

  3. Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 10, pp. 725-734

  4. Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)

    Pituitary, Vol. 27, Núm. 4, pp. 381-388

2023

  1. Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

    Pituitary, Vol. 26, Núm. 5, pp. 583-596

  2. Severe asthma patients’ and physicians’ perspectives of disease burden: do they match?

    ERJ Open Research

2022

  1. Management of early treated adolescents and young adults with phenylketonuria: Development of international consensus recommendations using a modified Delphi approach

    Molecular Genetics and Metabolism, Vol. 137, Núm. 1-2, pp. 114-126

  2. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2020

  1. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update

    Journal of Clinical Endocrinology and Metabolism, Vol. 105, Núm. 4, pp. E937-E946

  2. Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name

    Metabolism: Clinical and Experimental, Vol. 113

  3. Multidisciplinary management of acromegaly: A consensus

    Reviews in Endocrine and Metabolic Disorders, Vol. 21, Núm. 4, pp. 667-678

  4. Repositioning of the global epicentre of non-optimal cholesterol

    Nature, Vol. 582, Núm. 7810, pp. 73-77

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: Results from the prospective garfield-af registry

    Journal of the American Heart Association, Vol. 8, Núm. 3

2017

  1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

    The Lancet HIV, Vol. 4, Núm. 11, pp. e486-e494

2014

  1. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction

    ChemBioChem, Vol. 15, Núm. 10, pp. 1471-1480

2004

  1. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo-controlled, randomized clinical trial

    Journal of Clinical Endocrinology and Metabolism, Vol. 89, Núm. 8, pp. 3943-3948